Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma

Patients with metastatic uveal melanoma usually die within 1 year of diagnosis, emphasizing an urgent need to develop new treatment strategies. The liver is the most common site of metastasis. Mitogen-activated protein kinase kinase (MEK) inhibitors improve survival in V600 BRAF–mutated cutaneous melanoma patients but have limited efficacy in patients with uveal melanoma. Our previous work showed that hepatocyte growth factor (HGF) signaling elicits resistance to MEK inhibitors in metastatic uveal melanoma. In this study, we demonstrate that expression of two BH3-only family proteins, Bim-EL and Bmf, contributes to HGF-mediated resistance to MEK inhibitors. Targeting HGF/cMET signaling with LY2875358, a neutralizing and internalizing anti-cMET bivalent antibody, and LY2801653, a dual cMET/RON inhibitor, overcomes resistance to trametinib provided by exogenous HGF and by conditioned medium from primary hepatic stellate cells. We further determined that activation of PI3Kα/γ/δ isoforms mediates the resistance to MEK inhibitors by HGF. Combination of LY2801653 with trametinib decreases AKT phosphorylation and promotes proapoptotic PARP cleavage in metastatic uveal melanoma explants. Together, our data support the notion that selectively blocking cMET signaling or PI3K isoforms in metastatic uveal melanoma may break the intrinsic resistance to MEK inhibitors provided by factors from stromal cells in the liver. Mol Cancer Ther; 16(3); 516–28. ©2017 AACR.

[1]  X. Chen,et al.  Targeting c‐MET by LY2801653 for treatment of cholangiocarcinoma , 2016, Molecular carcinogenesis.

[2]  B. Taylor,et al.  Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma , 2016, Nature Genetics.

[3]  N. Hayward,et al.  Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4 , 2015, Oncotarget.

[4]  A. Aplin,et al.  Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma. , 2015, Cancer research.

[5]  G. Schwartz,et al.  Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT) , 2015, BMC Cancer.

[6]  M. McMahon,et al.  PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. , 2015, Cancer discovery.

[7]  J. Thrasher,et al.  Nanomicellar TGX221 blocks xenograft tumor growth of prostate cancer in nude mice , 2015, The Prostate.

[8]  D. Serie,et al.  c-MET expression in primary and liver metastases in uveal melanoma , 2014, Melanoma research.

[9]  A. Shoushtari,et al.  GNAQ and GNA11 mutations in uveal melanoma , 2014, Melanoma research.

[10]  Ying Tang,et al.  LY2875358, a Neutralizing and Internalizing Anti-MET Bivalent Antibody, Inhibits HGF-Dependent and HGF-Independent MET Activation and Tumor Growth , 2014, Clinical Cancer Research.

[11]  Erwin G. Van Meir,et al.  Biology of advanced uveal melanoma and next steps for clinical therapeutics , 2014, Pigment cell & melanoma research.

[12]  G. Linette,et al.  Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. , 2014, JAMA.

[13]  Kang Zhang,et al.  Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. , 2014, Cancer cell.

[14]  G. Merlino,et al.  Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. , 2014, Cancer cell.

[15]  Daniel L. Chao,et al.  A molecular revolution in uveal melanoma: implications for patient care and targeted therapy. , 2014, Ophthalmology.

[16]  H. Rui,et al.  Expression of insulin‐like growth factor‐1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth , 2014, Pigment cell & melanoma research.

[17]  R. Salgia,et al.  Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. , 2014, Cancer research.

[18]  M. Deininger,et al.  Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies , 2014, Haematologica.

[19]  David Gentien,et al.  SF3B1 mutations are associated with alternative splicing in uveal melanoma. , 2013, Cancer discovery.

[20]  R. Walgren,et al.  Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET , 2013, Clinical Cancer Research.

[21]  A. Bowcock,et al.  BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma , 2013, BMC Cancer.

[22]  A. Hinnebusch,et al.  Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3 , 2013, Nature Genetics.

[23]  D. Stainier,et al.  Hepatic stellate cells in liver development, regeneration, and cancer. , 2013, The Journal of clinical investigation.

[24]  A. Bowcock,et al.  Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma , 2013, Nature Genetics.

[25]  David J. Forsthoefel,et al.  A genome-wide RNAi screen reveals a Trio-regulated Rho GTPase circuitry transducing mitogenic signals initiated by G protein-coupled receptors. , 2013, Molecular cell.

[26]  J. Graff,et al.  LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models , 2012, Investigational New Drugs.

[27]  A. Aplin,et al.  BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma , 2012, Cell Death and Differentiation.

[28]  K. Flaherty,et al.  Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[29]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[30]  S. Woodman,et al.  Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner , 2012, Clinical Cancer Research.

[31]  Dirk Schadendorf,et al.  Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .

[32]  J. Harbour.  The genetics of uveal melanoma: an emerging framework for targeted therapy , 2012, Pigment cell & melanoma research.

[33]  Richard D Carvajal,et al.  Therapeutic Implications of the Emerging Molecular Biology of Uveal Melanoma , 2011, Clinical Cancer Research.

[34]  A. Bowcock,et al.  Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas , 2010, Science.

[35]  J. O'Brien,et al.  Mutations in GNA11 in uveal melanoma. , 2010, The New England journal of medicine.

[36]  E. Knudsen,et al.  Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure , 2010, Oncogene.

[37]  A. Gressner,et al.  Immortal hepatic stellate cell lines: useful tools to study hepatic stellate cell biology and function? , 2007, Journal of cellular and molecular medicine.

[38]  G. Mills,et al.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.

[39]  A. Aplin,et al.  B-RAF and PI-3 kinase signaling protect melanoma cells from anoikis , 2006, Oncogene.

[40]  Arun D. Singh,et al.  Uveal melanoma: epidemiologic aspects. , 2005, Ophthalmology clinics of North America.

[41]  R. Taub.  Liver regeneration: from myth to mechanism , 2004, Nature Reviews Molecular Cell Biology.

[42]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[43]  R. Bronson,et al.  Deletion of the p27Kip1 gene restores normal development in cyclin D1-deficient mice. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  W. Birchmeier,et al.  Coupling of Gab1 to C-Met, Grb2, and Shp2 Mediates Biological Responses , 2000, The Journal of cell biology.

[45]  G. Barsh,et al.  Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi , 2010 .